Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Academic Article DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Academic Article Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Academic Article Predicting long-term survival in multiple myeloma patients following autotransplants.
Academic Article Treatment advances in multiple myeloma.
Academic Article Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Academic Article Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Academic Article Con: allogeneic transplantation in multiple myeloma.
Academic Article Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Academic Article Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Academic Article High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Academic Article Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Academic Article Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.
Academic Article Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Academic Article TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Academic Article Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Academic Article Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Academic Article NY-ESO-1 immunotherapy for multiple myeloma.
Academic Article A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Academic Article Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
Academic Article Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
Academic Article Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.
Academic Article Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Academic Article Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Academic Article Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Academic Article The molecular classification of multiple myeloma.
Academic Article Allografting or autografting for myeloma.
Academic Article Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Academic Article Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Academic Article Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Academic Article Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Academic Article Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Academic Article High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
Academic Article Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Academic Article CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Academic Article Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Academic Article The Arkansas approach to therapy of patients with multiple myeloma.
Academic Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
Academic Article Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Academic Article Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Academic Article Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
Academic Article Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Academic Article Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Academic Article A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Academic Article Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Academic Article Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
Academic Article Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Academic Article Light-chain MGUS: implications for clinical practice.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
Academic Article Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Academic Article Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Academic Article First thalidomide clinical trial in multiple myeloma: a decade.
Academic Article Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Academic Article Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Academic Article NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Academic Article Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Academic Article International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Academic Article Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Academic Article Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Academic Article F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Academic Article Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Academic Article Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Concept Multiple Myeloma
Academic Article Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Academic Article First thalidomide clinical trial in multiple myeloma: a decade later
Academic Article Hematopoietic Stem Cell Transplantation
Academic Article Total Therapy 3 (2003-33) in Gene Expression Profiling-Defined Low-Risk Multiple Myeloma Confirmed in Subsequent Trial 2006-66 with Bortezemib, Lenalidomide and Dexamethasone (VRD) Maintenance
Academic Article Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance
Academic Article In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
Academic Article Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Academic Article Engineering more efficacious antibody therapy for myeloma.
Academic Article Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Academic Article The future of autologous stem cell transplantation in myeloma.
Academic Article CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.
Academic Article Haematological cancer: Optimizing the treatment of multiple myeloma.
Academic Article Fulminant onset of acute leukemia from normal hematopoiesis within 3?months of follow up for multiple myeloma treated with total therapy protocols.
Academic Article Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Academic Article Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Academic Article Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Academic Article Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Academic Article Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.
Academic Article Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Academic Article MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Academic Article Transplantation for Multiple Myeloma.
Academic Article Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Academic Article The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Academic Article Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
Academic Article The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
Academic Article The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Academic Article Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Academic Article Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Academic Article Immunologic approaches for the treatment of multiple myeloma.
Academic Article Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Academic Article The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Academic Article Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Academic Article The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Academic Article Kinase domain activation through gene rearrangement in multiple myeloma.
Academic Article Infectious and immunological sequelae of daratumumab in multiple myeloma.
Academic Article MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Academic Article Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Grant Potentiating Natural Killer Cell Anti-Myeloma Effects
Grant Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients
Grant 2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv
Grant UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma
Academic Article Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53.
Grant Phase 3 Randomized, open-label clinical trial of tanespimycin (KO953) plus Bortezomib Compared to bortezomib alone in patients with multiple myeloma i
Academic Article Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Academic Article An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Academic Article BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Academic Article A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Academic Article Accelerated single cell seeding in relapsed multiple myeloma.
Grant S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct...260489
Academic Article The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Academic Article Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.
Academic Article Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Academic Article Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Academic Article The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Academic Article Author Correction: Accelerated single cell seeding in relapsed multiple myeloma.
Academic Article Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.
Academic Article Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Academic Article PHF19 inhibition as a therapeutic target in multiple myeloma.
Academic Article Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Academic Article TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
Academic Article High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
Academic Article Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Academic Article Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Academic Article Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.
Academic Article Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients.
Academic Article Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Academic Article Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Academic Article Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Academic Article Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
Academic Article Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
Academic Article CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Academic Article Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.
Academic Article Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Academic Article The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Academic Article Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Academic Article Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Academic Article Variability of definition of high-risk multiple myeloma across phase III clinical trials.
Academic Article Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Academic Article Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma.
Academic Article Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial.
Academic Article Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Academic Article Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Grant UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma
Grant A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
Grant Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients
Grant UARK 2014-21: Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS with Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma
Academic Article A gene signature can predict risk of MGUS progressing to multiple myeloma.
Academic Article Expression of integrin ?-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.
Academic Article Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
Academic Article Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Academic Article Growth and dormancy control of myeloma cells by mesenchymal stem cells.
Academic Article Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Academic Article The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Academic Article High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma.
Academic Article Perspectives on the Treatment of Multiple Myeloma.
Academic Article Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Academic Article Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Academic Article Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Academic Article Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Academic Article Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Academic Article Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Search Criteria
  • Multiple Myeloma